rofecoxib has been researched along with Gastric Ulcer in 41 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor." | 9.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| "To evaluate the potential clinical and economic consequences of rofecoxib prescription in Ontario, Canada, for patients with osteoarthritis (OA) aged >65 years who did not respond to paracetamol (acetaminophen) therapy." | 7.71 | Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. ( Attard, CL; Kong, SX; Marentette, MA; Marshall, JK; Pellissier, JM, 2001) |
| "Osteoarthritis patients > or =50 years of age without ulcers or erosive esophagitis at baseline endoscopy were assigned randomly to placebo, enteric-coated aspirin 81 mg/day, rofecoxib 25 mg combined with aspirin 81 mg/day, or ibuprofen 800 mg 3 times a day." | 5.11 | Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. ( Laine, L; Maller, ES; Quan, H; Simon, T; Yu, C, 2004) |
| " We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor." | 5.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| "We analysed pooled data from two identical double-blind, randomized, 12-week endoscopy studies which compared the gastroduodenal toxicity of placebo (n=371), rofecoxib 25 mg (n=390), rofecoxib 50 mg (n=379), and ibuprofen 2400 mg daily (n=376) in patients with osteoarthritis." | 5.09 | Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. ( Bolognese, JA; Harper, SE; Hawkey, CJ; Laine, L; Mortensen, E; Quan, HU, 2001) |
| "To update the results of a previously performed analysis of the incidence of upper GI perforations, symptomatic gastroduodenal ulcers, and upper GI bleeding (PUBs) with rofecoxib compared with non-selective NSAIDs." | 4.82 | The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. ( Bolognese, JA; Reicin, AS; Simon, TJ; Watson, DJ; Yu, Q, 2004) |
| " The compounds were evaluated for their anti-inflammatory activity in carrageenan induced rat paw edema model taking rofecoxib and indomethacin as standard drugs." | 3.85 | Synthesis of methanesulphonamido-benzimidazole derivatives as gastro-sparing antiinflammatory agents with antioxidant effect. ( Bali, A; Chaudhari, BB; Sharma, R, 2017) |
| "A series of 3-alkoxy-4-methanesulfonamido acetophenone derivatives were synthesized and evaluated for their anti-inflammatory activity in carrageenan-induced rat paw edema model." | 3.78 | Synthesis, evaluation and docking studies on 3-alkoxy-4-methanesulfonamido acetophenone derivatives as non ulcerogenic anti-inflammatory agents. ( Bali, A; Deb, PK; Ohri, R, 2012) |
| " In a chronic model, by acetic acid-induced gastric ulcers, COX-2 was expressed at 7 days and was also associated with PGE(2) increase." | 3.73 | COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions. ( Alarcón de la Lastra, C; Bruseghini, L; Manuel Herrerias, J; Motilva, V; Sánchez-Fidalgo, S, 2005) |
| " In the present study, we examined the effect of various COX inhibitors on gastric ulcerogenic and acid secretory responses following daily exposure of the stomach to iodoacetamide (IA) and investigated the role for COX isozyme in gastric protection under subchronic mucosal irritation." | 3.72 | Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach. ( Hayashi, Y; Murakami, M; Takeeda, M; Takeuchi, K; Yamato, M, 2004) |
| "To elucidate the role of cyclooxygenase-2, we compared the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, and ibuprofen, a nonselective cyclooxygenase inhibitor, on the evolution of acetic-acid-induced gastric ulcers in rats, evaluating growth factor expression, the angiogenic process, cell proliferation and cell apoptosis." | 3.72 | Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. ( Illanes, M; Martín-Lacave, I; Motilva, V; Sánchez-Fidalgo, S, 2004) |
| "To evaluate the potential clinical and economic consequences of rofecoxib prescription in Ontario, Canada, for patients with osteoarthritis (OA) aged >65 years who did not respond to paracetamol (acetaminophen) therapy." | 3.71 | Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. ( Attard, CL; Kong, SX; Marentette, MA; Marshall, JK; Pellissier, JM, 2001) |
| " However, NSAIDs cause significant adverse upper gastrointestinal effects, including increased mortality from serious ulcer complications." | 2.41 | Selective inhibitors of COX-2--are they safe for the stomach? ( Giercksky, KE; Haglund, U; Rask-Madsen, J, 2000) |
| "Gastric ulcers were produced by thermocauterization under ether anesthesia." | 1.34 | Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. ( Amagase, K; Ashida, Y; Hatazawa, R; Kato, S; Takeuchi, K; Tanaka, A; Tanigami, M, 2007) |
| "In indomethacin and rofecoxib-treated gerbils, the following results were obtained in H pylori-infected group vs H pylori-eradicated group respectively: hyperplasia area of the stomach (mm2): 82." | 1.33 | Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils. ( Chang, CC; Chen, SH; Fang, CL; Hsieh, CR; Lien, GS; Lou, HY; Pan, S, 2005) |
| "Gastric ulcers were induced in male Sprague-Dawley rats by a luminal application of acetic acid solution." | 1.31 | Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. ( Cho, CH; Choy, HT; Guo, JS; Lam Liu, ES; Leung Koo, MW; Wang, JY, 2002) |
| "In vehicle-treated rats, gastric ulcers healed progressively and at day 14 the healing was completed, accompanied by a significant rise in the GBF at ulcer margin." | 1.31 | Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. ( Brzozowski, T; Drozdowicz, D; Hahn, EG; Konturek, PC; Konturek, SJ; Pajdo, R; Ptak, A; Sliwowski, Z, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.32) | 18.2507 |
| 2000's | 36 (87.80) | 29.6817 |
| 2010's | 2 (4.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, SS | 1 |
| Byun, Y | 1 |
| Lim, KM | 1 |
| Choi, JK | 1 |
| Lee, KW | 1 |
| Moh, JH | 1 |
| Kim, JK | 1 |
| Jeong, YS | 1 |
| Kim, JY | 1 |
| Choi, YH | 1 |
| Koh, HJ | 1 |
| Park, YH | 1 |
| Oh, YI | 1 |
| Noh, MS | 1 |
| Chung, S | 1 |
| Bali, A | 2 |
| Ohri, R | 1 |
| Deb, PK | 1 |
| Sharma, R | 1 |
| Chaudhari, BB | 1 |
| Wooltorton, E | 1 |
| Atkinson, HG | 1 |
| Guo, JS | 1 |
| Cho, CH | 1 |
| Lam Liu, ES | 1 |
| Choy, HT | 1 |
| Wang, JY | 1 |
| Leung Koo, MW | 1 |
| Kato, S | 3 |
| Ogawa, Y | 1 |
| Kanatsu, K | 1 |
| Okayama, M | 1 |
| Watanabe, T | 1 |
| Arakawa, T | 1 |
| Takeuchi, K | 8 |
| Araki, H | 2 |
| Komoike, Y | 2 |
| Matsumoto, M | 1 |
| Tanaka, A | 6 |
| Déciga-Campos, M | 1 |
| López, UG | 1 |
| Reval, MI | 1 |
| López-Muñoz, FJ | 1 |
| Souza, MH | 1 |
| de Lima, OM | 1 |
| Zamuner, SR | 1 |
| Fiorucci, S | 1 |
| Wallace, JL | 1 |
| Chaabouni, H | 1 |
| Amouri, A | 1 |
| Cheikh, I | 1 |
| Kchaou, M | 1 |
| Ouerghi, H | 1 |
| Ben Mami, N | 1 |
| Ben Ammar, A | 1 |
| Baboota, S | 2 |
| Dhaliwal, M | 2 |
| Kohli, K | 2 |
| Ali, J | 1 |
| Takeeda, M | 1 |
| Hayashi, Y | 2 |
| Yamato, M | 1 |
| Murakami, M | 2 |
| Kanatani, K | 1 |
| Ebata, M | 1 |
| Okabe, S | 1 |
| Kubo, Y | 1 |
| Laine, L | 3 |
| Maller, ES | 1 |
| Yu, C | 1 |
| Quan, H | 3 |
| Simon, T | 2 |
| Watson, DJ | 1 |
| Yu, Q | 1 |
| Bolognese, JA | 3 |
| Reicin, AS | 1 |
| Simon, TJ | 2 |
| Sánchez-Fidalgo, S | 2 |
| Martín-Lacave, I | 1 |
| Illanes, M | 1 |
| Motilva, V | 2 |
| Chang, CC | 1 |
| Chen, SH | 1 |
| Lien, GS | 1 |
| Lou, HY | 1 |
| Hsieh, CR | 1 |
| Fang, CL | 1 |
| Pan, S | 1 |
| Alarcón de la Lastra, C | 1 |
| Bruseghini, L | 1 |
| Manuel Herrerias, J | 1 |
| Yokota, A | 1 |
| Taniguchi, M | 1 |
| Takahira, Y | 1 |
| Ebert, MP | 1 |
| Schäfer, C | 1 |
| Chen, J | 1 |
| Hoffmann, J | 1 |
| Gu, P | 1 |
| Kubisch, C | 1 |
| Carl-McGrath, S | 1 |
| Treiber, G | 1 |
| Malfertheiner, P | 1 |
| Röcken, C | 1 |
| Bobadilla, RV | 1 |
| Barnett, EM | 1 |
| Randels, CL | 1 |
| Aihara, E | 1 |
| Amagase, K | 2 |
| Hatazawa, R | 1 |
| Tanigami, M | 1 |
| Ashida, Y | 1 |
| Lanza, FL | 1 |
| Rack, MF | 1 |
| Hoover, ME | 1 |
| Wilson, FR | 1 |
| Harper, SE | 2 |
| Harper, S | 1 |
| Bath, R | 1 |
| Johanson, J | 1 |
| Schwartz, H | 1 |
| Stern, S | 1 |
| Bolognese, J | 1 |
| Brzozowski, T | 2 |
| Konturek, PC | 2 |
| Konturek, SJ | 2 |
| Sliwowski, Z | 2 |
| Drozdowicz, D | 2 |
| Stachura, J | 1 |
| Pajdo, R | 2 |
| Hahn, EG | 2 |
| Hinz, B | 1 |
| Brune, K | 1 |
| Laudanno, OM | 1 |
| Cesolari, JA | 1 |
| Esnarriaga, J | 1 |
| Rista, L | 1 |
| Piombo, G | 1 |
| Maglione, C | 1 |
| Aramberry, LJ | 1 |
| Sambrano, JS | 1 |
| Godoy, A | 1 |
| Rocaspana, A | 1 |
| Giercksky, KE | 1 |
| Haglund, U | 1 |
| Rask-Madsen, J | 1 |
| Gottlieb, S | 1 |
| Ptak, A | 1 |
| Bannwarth, B | 1 |
| Hawkey, CJ | 2 |
| Quan, HU | 1 |
| Mortensen, E | 1 |
| Zeidler, H | 1 |
| Marshall, JK | 1 |
| Pellissier, JM | 1 |
| Attard, CL | 1 |
| Kong, SX | 1 |
| Marentette, MA | 1 |
| Hase, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
6 reviews available for rofecoxib and Gastric Ulcer
| Article | Year |
|---|---|
[Selective cyclooxygenase-2 inhibitors and the digestive tract].
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Digestiv | 2002 |
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Double-Blind Method; Duodenal Ul | 2004 |
COX-2 inhibitors and the heart: putting risk in perspective.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2005 |
Selective inhibitors of COX-2--are they safe for the stomach?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
[COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2001 |
Cyclooxygenase inhibition: between the devil and the deep blue sea.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2002 |
4 trials available for rofecoxib and Gastric Ulcer
| Article | Year |
|---|---|
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor | 2004 |
Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenas | 1999 |
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
Topics: Aged; Aged, 80 and over; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; D | 1999 |
Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
Topics: Aged; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; | 2001 |
31 other studies available for rofecoxib and Gastric Ulcer
| Article | Year |
|---|---|
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
Topics: Adult; Animals; Arthritis, Experimental; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2004 |
Synthesis, evaluation and docking studies on 3-alkoxy-4-methanesulfonamido acetophenone derivatives as non ulcerogenic anti-inflammatory agents.
Topics: Acetophenones; Animals; Anti-Inflammatory Agents; Carrageenan; Cyclooxygenase 2; Edema; Models, Mole | 2012 |
Synthesis of methanesulphonamido-benzimidazole derivatives as gastro-sparing antiinflammatory agents with antioxidant effect.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antioxidants; Benzimidazoles; C | 2017 |
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Myocardi | 2002 |
COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2002 |
Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats.
Topics: Angiogenesis Inhibitors; Animals; Cyclooxygenase Inhibitors; Dinoprostone; Fibroblast Growth Factor | 2002 |
Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Topics: Animals; Arthritis, Experimental; Capillary Permeability; Celecoxib; Cyclooxygenase 1; Cyclooxygenas | 2002 |
Healing of duodenal ulcers is not impaired by indomethacin or rofecoxib, the selective COX-2 inhibitor, in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Duodenal Ulcer; Enzyme | 2002 |
Enhancement of antinociception by co-administration of an opioid drug (morphine) and a preferential cyclooxygenase-2 inhibitor (rofecoxib) in rats.
Topics: Administration, Oral; Analgesics; Analgesics, Opioid; Animals; Arthralgia; Cyclooxygenase 2; Cycloox | 2003 |
Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Adhesion; Cyclooxygenase 2; Cyclooxy | 2003 |
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben | 2003 |
Molecular inclusion of rofecoxib with cyclodextrin: pharmacological properties in laboratory animals.
Topics: Animals; Carrageenan; Cyclodextrins; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase I | 2004 |
Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach.
Topics: Administration, Oral; Animals; Body Weight; Capsaicin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyg | 2004 |
Effects of indomethacin and rofecoxib on gastric mucosal damage in normal and Helicobacter pylori-infected mongolian gerbils.
Topics: Administration, Oral; Animals; Dinoprostone; Drug Administration Schedule; Drug Synergism; Gastric A | 2004 |
Functional mechanism underlying COX-2 expression following administration of indomethacin in rat stomachs: importance of gastric hypermotility.
Topics: Animals; Atropine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinopro | 2004 |
Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Proliferation; Cyclooxygenase 2; C | 2004 |
Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Chronic Diseas | 2005 |
COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions.
Topics: Acetic Acid; Acute Disease; Animals; Chronic Disease; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2005 |
Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atropine; Colony Count, Microbial; Cyclooxygenase | 2005 |
Protective role of heat shock protein 27 in gastric mucosal injury.
Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; | 2005 |
Physicochemical characterization, in vitro dissolution behavior, and pharmacodynamic studies of rofecoxib-cyclodextrin inclusion compounds. preparation and properties of rofecoxib hydroxypropyl beta-cyclodextrin inclusion complex: a technical note.
Topics: Animals; beta-Cyclodextrins; Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Lac | 2005 |
Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa.
Topics: Animals; Benzamides; Benzoates; Gastric Mucosa; Indomethacin; Intestinal Mucosa; Lactones; Peptic Ul | 2007 |
Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors.
Topics: Animals; Benzamides; Benzoates; Bucladesine; Colforsin; Cyclooxygenase 1; Cyclooxygenase 2; Dinopros | 2007 |
Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions.
Topics: Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 1999 |
[Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2000 |
[Gastrointestinal damage induced by celecoxib and rofecoxib in rats].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Disease Mode | 2000 |
FDA refuses companies' request to drop ulcer warning.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Labeling; | 2001 |
Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cyclooxygenase 1; Cycloo | 2001 |
[New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)].
Topics: Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase I | 2001 |
Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygena | 2001 |
Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury.
Topics: Amino Acid Sequence; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygen | 2002 |